IT IS well known that pituitary growth hormone (GH) plays a crucial role in the regulation of glucose metabolism and also that there may be some relationship between GH concentrations and diabetic complications such as retinopathy, heuropathy and nephropathy. It was reported that hypersecretion of GH was frequently presented in patients with poorly controlled diabetes [1, 2] , although the underlying mechanism remained to be unclear [3, 4] . The physiological control of GH secretion is believed to depend on two hypothalamic peptides such as somatostatin and GH-releasing hormone (RH) [5] . The effect of glucose on GH-RH induced GH secretion is of interest because GH has been postulated to play an important role in diabetic complications [6, 7] . We, therefore, performed five-year follow up studies on various complications in the patients with NIDDM in order to clarify the role of GH in the development of diabetic complications.
Materials and Methods
Forty-two patients with NIDDM not possessing macro-nor microangiopathy were subjected to the present studies.
None of them had pituitary diseases or other metabolic dysfunction affecting the serum concentration of GH. Clinical profiles of the subjects are summarized in Table 1 patients in the L-R group and seven in the H-R group were treated with insulin. Four in the L-R group and six in the H-R group were treated with oral hypoglycemic agents, and the remaining nine in the L-R group and seven in the H-R group were treated with restricted diet alone. Euglycemic glucose clamping was performed in each subject with an artifificial pancreas apparatus STG-22 (Nikkiso, Tokyo, Japan), according to the methods previously reported [8, 9] . The glucose metabolized (M) during the final 20 min of the glucose clamping was calculated on the basis of the amount of glucose infused and expressed as mg/kg body weight/min. A venous blood sample was taken in the morning after 12 h of fasting, and the plasma glucose concentration was assayed by the glucose oxidase method. Blood samples were analyzed in a Nippon Denshi autoanalyzer (JCA-RX20, Tokyo, Japan) for plasma glucose and serum lipid concentrations.
The serum hormone concentration including GH and insulin like growth factor (IGF-I) was estimated by means of its specific radioimmunoassay kit which is commercially available.
Data are given as the mean ± SD. Continuous variables were compared by unpaired Student's ttest. Diabetic complications were compared by Fisher's exact test. Results were considered as statistically significant at P<0.05. Results 
M value and basal concentrations of GH and IGF-1
Basal GH in the H-R group was significantly lower than that in the L-R group (2.24 ± 2.94* vs. 3.81 ± 4.90 ng/ml).
There was no significant difference between the L-R and the H-R group in M values during euglycemic glucose clamping (7.60 ± 2.47 vs. 7.56 ± 2.64 mg/kg/min, n.s.). There was also observed no sigificnat correlation between the two groups in basal IGF-I (191.4 ± 33.4 vs. 189.0 ± 40.2 ng/ml, n.s.).
The response of GH to GH-RH loading test
Each GH value at 15, 30, 60, 90, 120 min after infusion of 100 ug GH-RH was significantly higher in the H-R group than in the L-R group (21.0 ± 5.4***, 21.0 ± 5.5***, 14.8 ± 8.9***, 9.2 ± 4.9**, 8.0 ± 3.2** ng/ml in the H-R group vs. 4.2 ± 2.2, 5.0 ± 3.9, 6.2 ± 3.4, 5.1 ± 2.8, 3.1 ± 1.9 ng/ml in the L-R group).
Blood glucose concentrations at 0, 15, 30, 60, 90,120 min after stimulation with GH-RH were significantly higher in the H-R group than in the L-R group (173 ± 36**, 171 ± 38**, 170 ± 38**, 166 ± 32*, 165 ± 33*, 164 ± 31* mg/dl in the H-R group vs. 156 ± 50,158 ± 48,156 ± 41,154 ± 42,150 ± 48, 148 ± 49 mg/dl in the L-R group).
Follow-up studies on various diabetic complications for 5 years Diabetic retinopathy: Three patients (15%) in the H-R group had retinopathy, showing A2, A2 and A5 type according to Fukuda's classification 5 years later, but all patients in the L-R group did not show any retinopathies. The occurrence of diabetic retinopathy was significantly higher in the H-R group than in the L-R group (P<0.05: the H-R group vs. the L-R group).
Diabetic nephropathy: Five patients (25%) in the H-R group had nephropathy which was evaluated with the existence of persistent proteinuria 5 years later, and three patients (14%) in the L-R group had nephropathy. Diabetic neuropathy: Five patients (25%) in the H-R group had diabetic neuropathy demonstrating abnormal nerve-conduction velocities during the 5-year follow up, and three (14%) in the L-R group had diabetic neuropathy.
Cerebro-vascular accident: Two patients (10%) in the H-R group suffered from cerebral infarction during the follow-up of those patients for 5 years, although there was no accident including cerebral infarction in the L-R group. The occurrence of cerebro-vascular accident was significantly higher in the H-R group than in the L-R group (P<0.05: the H-R group vs. the L-R group).
Myocardial infarction: One patient (5%) in the H-R group and one patient (4.5%) in the L-R group suffered from myocardial infarction during the 5 year follow-up. *P<0 .05, **P<0.01, ***P<0.001 vs. the L-R group
Discussion
The present study clearly demonstrated that the patients with NIDDM in the H-R group had much higher incidences of various complications; especially such as retinopathy and cerebro-vascular accident, than those in the L-R group during a 5 year follow-up, suggesting that exaggerated response of GH to GH-RH in spite of a high glucose level may be closely related to the development of diabetic complications in patients with NIDDM. On the other hand, basal IGF-I concentrations and M values reflecting insulin sensitivity did not seem to correlate with the development of diabetic complications. It was reported that hypersecretion of GH existed especially in diabetic patients whose blood glucose levels were poorly controlled [1, 2] , while it has recently been reported that a decrease in serum GH which is usually observed in a patient with GH deficiency (GHD) induces some abnormalities in glucose and lipid metabolism [10] [11] [12] . It is well known that replacement therapy with GH in GHD adults alters the body composition and energy metabolism through its lipolytic and anabolic actions [10] [11] [12] . It is, therefore, speculated that an appropriate amount of GH may be essential for well-balanced regulation of various metabolic functions, although it is still obscure how GH acts on the development of diabetic complications.
The present study also demonstrated that the blood glucose concetitration was significantly higher in the patients in the H-R group than in those in the L-R group. Inhibition of GH response to GH-RH by high glucose was reported in healthy subjects after oral [13] or intravenous [14] administration of glucose. Thus, it is very interesting that a paradoxically high response of GH to GH-RH was observed in the H-R group even though the blood glucose concentration was much higher in the H-R group than in the L-R group. Furthermore, we tried to perform GH-RH test in almost all patients again 5 years later (data not shown). The responsiveness of GH to GH-RH infusion test in both the H-R and the L-R groups did not differ during a 5 year follow-up.
It is well known that obesity induces decreased responsiveness of GH to GH-RH test, suggesting that BMI affects those responsiveness.
The present data demonstrated that BMI in the L-R group slightly but not significantly greater than in the H-R group, even though the values of BMI in the L-R group were almost within normal ranges. Thus high BMI is possible to explain the reason why the L-R group showed low responsiveness of GH to GH-RH test. However, the difference in responsiveness of GH to GH-RH between the L-R and H-R groups is still present 5 years later, although BMI in both groups is almost same 5 years later (data not shown).
Thus it is suggested that difference in responsiveness of GH may not be caused by changes in BMI of each group.
It is well known that the incidence of heart diseases and cerebro-vascular diseases is very high in diabetics and hypertensives.
It is, therefore, very important to examine any changes in both diabetic ma croangiopathy and microangiopathy. Nevertheless, there is an inexplicably high frequency of diabetic micro-and macroangiopathy in some patients even after adequately correcting the blood glucose concentrations.
The present data indicate that high response of GH to GH-RH may be related to some condition worsening diabetic angiopathies.
In conclusion, to study the response of GH to GH-RH infusion test is very useful in predicting diabetic complications which may appear later. It is also suggested that inappropriately high response of GH to GH-RH may be closely related to the pathogenesis of micro-and macroagiopathies in patients with NIDDM.
